Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02311335 · ClinicalTrials.gov registry record
Genes Involved in Lipid Disorders
A clinical trial, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 140
- Enrollment target
NCT02311335 is a clinical trial that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 140 participants.
The verdict
NCT02311335 has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 140 participants
- Enrollment target
Study Summary
Background: \- Genes are the instructions our body uses to function. Researchers can look for changes, or variants, in the genes. The goal of this study is to find new gene changes that lead to lipid disorders. Older research methods looked at one or a few genes at a time. Genomic sequencing looks at most of the genes at once. Genomic sequencing may find the cause researchers haven t been able to find from past methods. Objectives: \- To better understand genetic causes of lipid disorders through genomic sequencing. Eligibility: \- People age 2 and older with unusual lipid disorders, and their relatives. Design: * Participants will be screened with a physical exam and medical history. They will have blood taken. They may give a saliva sample. * Based on the screening test, researchers will chose 3-5 family members to perform the genomic sequencing. The sequencing will be done on a sample of DNA collected during the blood draw and saliva sample. * Participants may be invited to take part in other protocols that may involve imaging of their heart or blood vessels. They do not have to participate. If they do, they will sign a separate consent for those tests. * If a participant s family member cannot travel to the NIH, the NIH documents and consent will be reviewed during a teleconference. A blood or sputum kit will be mailed to them.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2014-11-26 |
| Est. Completion | 2021-09-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02311335
The ClinicalTrials.gov registry entry for NCT02311335 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02311335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02311335 about?
NCT02311335 is a clinical study titled "Genes Involved in Lipid Disorders". Background: \- Genes are the instructions our body uses to function. Researchers can look for changes, or variants, in the genes. The goal of this study is to find new gene changes that lead to lipid disorders. Older research methods looked at one or a few genes at a time. Genomic sequencing looks ...
What is the current status of trial NCT02311335?
This trial is currently completed. The enrollment target is 140 participants. The study started on 2014-11-26. Estimated completion is 2021-09-02.
Who is sponsoring clinical trial NCT02311335?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.